Dublin, Ireland-headquartered protein specialist Prothena (Nasdaq: PRTA) revealed that US pharma major Bristol Myers Squibb (NYSE: BMY) has exercised its option under the global neuroscience research and development collaboration to obtain the exclusive worldwide commercial rights for PRX005.
As a result, BMS will pay Prothena $55 million. PRX005, which is designed to be a best-in-class anti-tau antibody, specifically targets an area within the microtubule binding region (MTBR) of tau for the potential treatment of Alzheimer’s disease.
The option on PRX005 comes from a 2018 collaboration worth up to $.2 billion between Prothena and Celgene, which was acquired by BMS in 2019.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze